Open Label Extension of LipoLat-CS202
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 6/18/2016 |
| Start Date: | November 2015 |
| End Date: | June 2016 |
An Open-label Extension Study of the Safety and Efficacy of Subconjunctival Liposomal Latanoprost (POLAT-001) in Patients With Ocular Hypertension and Primary Open Angle Glaucoma
This is an open-label, observational extension of patients who received POLAT-001 in
LipoLat-CS202.
LipoLat-CS202.
- Inclusion criteria
1. Successful completion of 3 months of participation in Study LipoLat-CS202.
2. Treatment with POLAT-001 in Study LipoLat-CS202.
3. Able and willing to give signed informed consent and follow study instructions.
- Exclusion criteria
Excluded from the study will be individuals with the following characteristics:
1. The development, during study LipoLat-CS202, of any exclusion criteria from that study
(e.g., concomitant medication or co-morbid disease).
We found this trial at
1
site
Click here to add this to my saved trials
